MedTrace Logo

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

NCT05762146 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-10-19

No results posted yet for this study

Summary

A combination therapy proposed to be evaluated in this trial, consisting of three already registered compounds with a validated disease mechanism and with known safety profiles, targets key proteins in the dysregulated signal network in stroke, and is expected to synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection. The synergistic mode of action will allow for low doses and is expected to reduce possible side effects while maintaining maximal efficacy

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

Riociguat

Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.

DRUG

Propylthiouracil

Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors

DRUG

Perphenazine

Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.

Sponsors & Collaborators

  • Maastricht University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2024-02-29
Completion
2024-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05762146 on ClinicalTrials.gov